Literature DB >> 28396547

Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3.

Romney M Humphries1, Peera Hemarajata2.   

Abstract

Entities:  

Keywords:  KPC; OmpK35; OmpK36; ceftazidime-avibactam; resistance

Mesh：

Substances：

Year:  2017        PMID： 28396547      PMCID： PMC5444130          DOI： 10.1128/AAC.00537-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  11 in total

1.  Role of ISKpn7 and deletions in blaKPC gene expression.

Authors:  Thierry Naas; Gaelle Cuzon; Ha-Vy Truong; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

2.  Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.

Authors:  Mariana Castanheira; Janet C Mills; Sarah E Costello; Ronald N Jones; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

3.  Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy.

Authors:  J Findlay; A Hamouda; S J Dancer; S G B Amyes
Journal:  Clin Microbiol Infect       Date:  2011-07-11       Impact factor: 8.067

4.  Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying blaKPC Collected in U.S. Hospitals from 2012 to 2015.

Authors:  Mariana Castanheira; Rodrigo E Mendes; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.

Authors:  Ryan K Shields; Cornelius J Clancy; Binghua Hao; Liang Chen; Ellen G Press; Nicole M Iovine; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

6.  First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.

Authors:  Romney M Humphries; Shangxin Yang; Peera Hemarajata; Kevin W Ward; Janet A Hindler; Shelley A Miller; Aric Gregson
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

7.  Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013.

Authors:  S Pollett; S Miller; J Hindler; D Uslan; M Carvalho; R M Humphries
Journal:  J Clin Microbiol       Date:  2014-09-10       Impact factor: 5.948

8.  Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany.

Authors:  Sabine Gröbner; Dirk Linke; Wolfgang Schütz; Claudia Fladerer; Johannes Madlung; Ingo B Autenrieth; Wolfgang Witte; Yvonne Pfeifer
Journal:  J Med Microbiol       Date:  2009-06-05       Impact factor: 2.472

9.  Evolution and Transmission of Carbapenem-Resistant Klebsiella pneumoniae Expressing the blaOXA-232 Gene During an Institutional Outbreak Associated With Endoscopic Retrograde Cholangiopancreatography.

Authors:  Shangxin Yang; Peera Hemarajata; Janet Hindler; Fan Li; Helty Adisetiyo; Grace Aldrovandi; Robert Sebra; Andrew Kasarskis; Duncan MacCannell; Xavier Didelot; Dana Russell; Zachary Rubin; Romney Humphries
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

10.  Genomic Analysis of the Emergence and Rapid Global Dissemination of the Clonal Group 258 Klebsiella pneumoniae Pandemic.

Authors:  Jolene R Bowers; Brandon Kitchel; Elizabeth M Driebe; Duncan R MacCannell; Chandler Roe; Darrin Lemmer; Tom de Man; J Kamile Rasheed; David M Engelthaler; Paul Keim; Brandi M Limbago
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240
View more
  39 in total

1.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.

Authors:  Kirk Nelson; Peera Hemarajata; Dongxu Sun; Debora Rubio-Aparicio; Ruslan Tsivkovski; Shangxin Yang; Robert Sebra; Andrew Kasarskis; Hoan Nguyen; Blake M Hanson; Shana Leopold; George Weinstock; Olga Lomovskaya; Romney M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.

Authors:  Irene Galani; Ilias Karaiskos; Evdokia Angelidis; Vassiliki Papoutsaki; Lamprini Galani; Maria Souli; Anastasia Antoniadou; Helen Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-07-30       Impact factor: 3.267

4.  KPC Beta-Lactamases Are Permissive to Insertions and Deletions Conferring Substrate Spectrum Modifications and Resistance to Ceftazidime-Avibactam.

Authors:  Claire Amaris Hobson; Stéphane Bonacorsi; Hervé Jacquier; Alaksh Choudhury; Mélanie Magnan; Aurélie Cointe; Béatrice Bercot; Olivier Tenaillon; André Birgy
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 5.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

6.  Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.

Authors:  Safa S Almarzoky Abuhussain; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  A Smooth-Type, Phage-Resistant Klebsiella pneumoniae Mutant Strain Reveals that OmpC Is Indispensable for Infection by Phage GH-K3.

Authors:  Ruopeng Cai; Mei Wu; Hao Zhang; Yufeng Zhang; Mengjun Cheng; Zhimin Guo; Yalu Ji; Hengyu Xi; Xinwu Wang; Yibing Xue; Changjiang Sun; Xin Feng; Liancheng Lei; Yigang Tong; Xiaoyun Liu; Wenyu Han; Jingmin Gu
Journal:  Appl Environ Microbiol       Date:  2018-10-17       Impact factor: 4.792

Review 8.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

9.  Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Renee Ackley; Danya Roshdy; Jacqueline Meredith; Sarah Minor; William E Anderson; Gerald A Capraro; Christopher Polk
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 10.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.